Paratek Pharmaceuticals, Inc. - 10-Q filing on 2012-11-13

Available for Sale Securities

9 Months Ended

Sep. 30, 2012

Available-for-sale Securities [Abstract]

4. Available-for-sale Securities

The following is a summary of available-for-sale debt securities recognized as cash and cash equivalents, marketable securities, or restricted cash in the Company’s condensed consolidated balance sheets. Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services (in thousands):


	September 30, 2012
	Amortized		Unrealized		Unrealized		Estimated
	Cost		Gains		Losses		Fair Value
Certificates of deposit	$	200	$	—	$	—	$	200
Money market funds		27,517		—		—		27,517
U.S. Treasury securities		70,674		6		—		70,680

	$	98,391	$	6	$	—	$	98,397


	December 31, 2011
	Amortized		Unrealized		Unrealized		Estimated
	Cost		Gains		Losses		Fair Value
Certificates of deposit	$	200	$	—	$	—	$	200
Money market funds		9,238		—		—		9,238
U.S. Treasury securities		51,674		29		—		51,703

	$	61,112	$	29	$	—	$	61,141

The following table summarizes the classification of the available-for-sale securities on the Company’s condensed consolidated balance sheets (in thousands):


	September 30, 2012		December 31, 2011
Cash and cash equivalents	$	69,563	$	9,238
Marketable securities		28,634		51,703
Restricted cash		200		200

	$	98,397	$	61,141

There were no sales of available-for-sale marketable securities during the first nine months of 2012 or 2011.

At September 30, 2012, all of the Company’s marketable securities had a maturity of one year or less.